vs
Side-by-side financial comparison of Gloo Holdings, Inc. (GLOO) and GYRE THERAPEUTICS, INC. (GYRE). Click either name above to swap in a different company.
GYRE THERAPEUTICS, INC. is the larger business by last-quarter revenue ($37.2M vs $32.6M, roughly 1.1× Gloo Holdings, Inc.). GYRE THERAPEUTICS, INC. runs the higher net margin — -3.7% vs -116.9%, a 113.2% gap on every dollar of revenue. GYRE THERAPEUTICS, INC. produced more free cash flow last quarter ($-5.8M vs $-63.4M).
GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.
GLOO vs GYRE — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $32.6M | $37.2M |
| Net Profit | $-38.0M | $-1.4M |
| Gross Margin | — | 95.3% |
| Operating Margin | -82.0% | 0.3% |
| Net Margin | -116.9% | -3.7% |
| Revenue YoY | — | 33.4% |
| Net Profit YoY | 12.2% | -340.1% |
| EPS (diluted) | $-6.08 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $32.6M | $37.2M | ||
| Q3 25 | — | $30.6M | ||
| Q2 25 | — | $26.8M | ||
| Q1 25 | — | $22.1M | ||
| Q4 24 | — | $27.9M | ||
| Q3 24 | — | $25.5M | ||
| Q2 24 | — | $25.2M | ||
| Q1 24 | — | $27.2M |
| Q4 25 | $-38.0M | $-1.4M | ||
| Q3 25 | — | $5.9M | ||
| Q2 25 | — | $1.6M | ||
| Q1 25 | — | $3.7M | ||
| Q4 24 | — | $569.0K | ||
| Q3 24 | — | $2.9M | ||
| Q2 24 | — | $4.5M | ||
| Q1 24 | — | $9.9M |
| Q4 25 | — | 95.3% | ||
| Q3 25 | — | 94.7% | ||
| Q2 25 | — | 95.7% | ||
| Q1 25 | — | 95.9% | ||
| Q4 24 | — | 95.8% | ||
| Q3 24 | — | 96.2% | ||
| Q2 24 | — | 96.9% | ||
| Q1 24 | — | 96.4% |
| Q4 25 | -82.0% | 0.3% | ||
| Q3 25 | — | 22.7% | ||
| Q2 25 | — | 8.1% | ||
| Q1 25 | — | 10.3% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | — | 16.6% | ||
| Q2 24 | — | 12.7% | ||
| Q1 24 | — | 29.7% |
| Q4 25 | -116.9% | -3.7% | ||
| Q3 25 | — | 19.4% | ||
| Q2 25 | — | 5.9% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 2.0% | ||
| Q3 24 | — | 11.2% | ||
| Q2 24 | — | 18.0% | ||
| Q1 24 | — | 36.6% |
| Q4 25 | $-6.08 | $-0.01 | ||
| Q3 25 | — | $0.03 | ||
| Q2 25 | — | $0.00 | ||
| Q1 25 | — | $0.00 | ||
| Q4 24 | — | $0.00 | ||
| Q3 24 | — | $0.01 | ||
| Q2 24 | — | $0.01 | ||
| Q1 24 | — | $0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $15.1M | $52.4M |
| Total DebtLower is stronger | $176.5M | — |
| Stockholders' EquityBook value | $-444.4M | $106.0M |
| Total Assets | $206.7M | $166.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $15.1M | $52.4M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $54.4M | ||
| Q1 25 | — | $29.9M | ||
| Q4 24 | — | $26.7M | ||
| Q3 24 | — | $25.1M | ||
| Q2 24 | — | $25.1M | ||
| Q1 24 | — | $37.4M |
| Q4 25 | $176.5M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-444.4M | $106.0M | ||
| Q3 25 | — | $101.9M | ||
| Q2 25 | — | $92.0M | ||
| Q1 25 | — | $68.1M | ||
| Q4 24 | — | $63.3M | ||
| Q3 24 | — | $63.2M | ||
| Q2 24 | — | $60.4M | ||
| Q1 24 | — | $56.6M |
| Q4 25 | $206.7M | $166.1M | ||
| Q3 25 | — | $159.4M | ||
| Q2 25 | — | $152.6M | ||
| Q1 25 | — | $129.8M | ||
| Q4 24 | — | $125.4M | ||
| Q3 24 | — | $125.2M | ||
| Q2 24 | — | $120.9M | ||
| Q1 24 | — | $122.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-63.0M | $-5.6M |
| Free Cash FlowOCF − Capex | $-63.4M | $-5.8M |
| FCF MarginFCF / Revenue | -194.8% | -15.5% |
| Capex IntensityCapex / Revenue | 1.4% | 0.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-180.0K |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-63.0M | $-5.6M | ||
| Q3 25 | — | $4.7M | ||
| Q2 25 | — | $2.1M | ||
| Q1 25 | — | $-129.0K | ||
| Q4 24 | — | $-2.8M | ||
| Q3 24 | — | $1.7M | ||
| Q2 24 | — | $-5.5M | ||
| Q1 24 | — | $2.9M |
| Q4 25 | $-63.4M | $-5.8M | ||
| Q3 25 | — | $4.0M | ||
| Q2 25 | — | $1.8M | ||
| Q1 25 | — | $-251.0K | ||
| Q4 24 | — | $-2.8M | ||
| Q3 24 | — | $1.0M | ||
| Q2 24 | — | $-6.9M | ||
| Q1 24 | — | $2.7M |
| Q4 25 | -194.8% | -15.5% | ||
| Q3 25 | — | 13.1% | ||
| Q2 25 | — | 6.8% | ||
| Q1 25 | — | -1.1% | ||
| Q4 24 | — | -10.1% | ||
| Q3 24 | — | 4.1% | ||
| Q2 24 | — | -27.5% | ||
| Q1 24 | — | 9.8% |
| Q4 25 | 1.4% | 0.4% | ||
| Q3 25 | — | 2.2% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 0.6% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | 5.8% | ||
| Q1 24 | — | 0.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.79× | ||
| Q2 25 | — | 1.32× | ||
| Q1 25 | — | -0.03× | ||
| Q4 24 | — | -4.85× | ||
| Q3 24 | — | 0.60× | ||
| Q2 24 | — | -1.21× | ||
| Q1 24 | — | 0.29× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GLOO
| Platform Solutions | $12.7M | 39% |
| Advertising | $11.1M | 34% |
| Marketplace | $3.9M | 12% |
| Midwestern Acquisition | $2.7M | 8% |
| Servant Acquisition | $1.8M | 6% |
GYRE
Segment breakdown not available.
